Ascendis Pharma (ASND) reported $814M in revenue for fiscal 2025, +106.7% year on year. That ranks #1907 by revenue among 2853 SEC filers and #178 in Healthcare. It posted a net loss of −$258M for the same year. Revenue has grown 56.9% a year on average since 2015 ($9.0M then). The fiscal 2025 balance sheet shows $1.5B in total assets, $724M in cash and $453M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| Revenue€720M | $814M | +106.7% | FY20252025-12-31 |
| Gross profit€625M | $706M | +104.4% | FY20252025-12-31 |
| Operating income−€136M | −$154M | +$148M | FY20252025-12-31 |
| Net income−€228M | −$258M | +$152M | FY20252025-12-31 |
| Operating cash flow€53.9M | $60.9M | +$392M | FY20252025-12-31 |
| Capital expenditure€2.4M | $2.6M | −82.7% | FY20232023-12-31 |
| Total assets€1.3B | $1.5B | +24.9% | FY20252025-12-31 |
| Shareholders' equity−€163M | −$191M | −$81.5M | FY20252025-12-31 |
| Cash€616M | $724M | +24.5% | FY20252025-12-31 |
| Long-term debt€385M | $453M | +19.4% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Figures are reported under IFRS in EUR and converted to US dollars at ECB reference rates — fiscal 2025 average 0.885 EUR/$ for income items, year-end 0.851 EUR/$ for balance-sheet items.
Profile
- Legal name
- Ascendis Pharma A/S
- Ticker
- ASND
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001612042
Filings
- 20-FFeb 11, 2026Open filing →
- 20-FFeb 12, 2025Open filing →
- 20-FFeb 7, 2024Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Arrowhead PharmaceuticalsARWR | $829M | −$1.6M |
| Myriad GeneticsMYGN | $825M | −$366M |
| Orthofix MedicalOFIX | $822M | −$92.2M |
| Ascendis PharmaASND | $814M | −$258M |
| Caris Life SciencesCAI | $812M | −$68.1M |
| Telix PharmaceuticalsTLX | $804M | −$7.1M |
| U S Physical TherapyUSPH | $781M | $39.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ascendis Pharma — Key figures |url=https://companiesranked.com/en/company/ascendis-pharma |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ascendis Pharma — Key figures. CompaniesRanked. https://companiesranked.com/en/company/ascendis-pharmaBibTeX
@misc{companiesranked-en-company-ascendis-pharma-2026,
author = {{CompaniesRanked}},
title = {{Ascendis Pharma — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ascendis-pharma}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001193125-26-046590 · February 11, 2026
{{cite web |title=Ascendis Pharma — Key figures — 20-F (0001193125-26-046590) |url=https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.